China Opens Up Non-End-To-End Manufacturing Of Biologics Within, Across Border

 
• By Xu Hu
  
New rules shift
China's NMPA launched a pilot program of non-end-to-end manufacturing of certain biologics due at the end of 2026. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Manufacturing

More from Pink Sheet